This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Roche Holding Management
Management Kriterienprüfungen 2/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Thomas Schinecker
Geschäftsführender
n/a
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | n/a |
| Amtszeit als Geschäftsführer | 3yrs |
| Eigentum des Geschäftsführers | 0.0004% |
| Durchschnittliche Amtszeit des Managements | 6yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 6yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • Mar 21
ROG: 2026 Clinical Catalysts And Obesity Data Will Drive Upside Potential
Analysts now place fair value for Roche Holding at CHF 363.47. This is a modest adjustment supported by mixed recent research that highlights softer revenue growth and profit margin assumptions, a higher future P/E, and a wider spread of Street price targets ranging from CHF 325 to CHF 390, alongside ratings that span from Neutral to Buy.
Narrativ-Update • Mar 07
ROG: Genomics Pricing And Cautious Pipeline Outlook Will Constrain Future Upside
The analyst fair value estimate for Roche Holding has been raised from CHF 230.00 to CHF 262.39, as analysts factor in updated assumptions for revenue growth, profit margins, and a lower future P/E multiple, alongside recent Street price target increases and more constructive views on the pipeline and diagnostics pricing. Analyst Commentary Recent research has highlighted a mixed but generally more constructive tone around Roche, with fresh attention on pricing decisions, the pipeline, and relative positioning versus peers in diagnostics and genomics.Narrativ-Update • Feb 21
ROG: Pipeline Milestones And Digital Execution Will Shape Balanced Risk Reward Ahead
Roche Holding's updated analyst price target has moved higher to reflect a fair value shift to CHF 358.45 from CHF 323.28. Analysts point to improved growth and margin assumptions, alongside recent upgrades and higher CHF-based targets from several banks.
Narrativ-Update • Feb 07
ROG: 2026 Clinical Pipeline And Execution Progress Will Drive Future Rerating
Analysts have nudged their fair value estimate for Roche Holding slightly higher to CHF 428, citing a mix of updated assumptions around revenue growth, profit margins, discount rates and future P/E multiples, along with recent upward moves in Street price targets and more constructive research coverage. Analyst Commentary Bullish analysts have become more constructive on Roche in recent months, with several research notes pointing to upgraded ratings, refreshed price targets and improving sentiment around the pipeline and execution.Analyseartikel • Feb 03
Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year
As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...
Neues Narrativ • Feb 01
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.Narrativ-Update • Jan 23
ROG: 2026 Clinical Milestones And Execution Progress Will Drive Future Rerating
Analysts have raised their price expectations for Roche Holding, citing updated assumptions that include improved revenue growth, a slightly lower projected profit margin, and a modestly reduced future P/E multiple. These changes are supported by recent rating upgrades and positive commentary on clinical catalysts and the operational outlook.Narrativ-Update • Jan 09
ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution
Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.Narrativ-Update • Dec 17
ROG: Pipeline Data And Digital Execution Will Shape Balanced Risk Reward Ahead
Analysts have nudged their fair value estimate for Roche Holding higher, lifting the target by about CHF 11.50 to reflect slightly stronger long term revenue growth and margin assumptions supported by recent positive readthroughs from partners, incremental pipeline visibility, and a modest firming in Street price targets. Analyst Commentary Bullish analysts emphasize that recent partner updates and pipeline milestones are incrementally improving sentiment on Roche, supporting the view that medium term growth and margin visibility are strengthening despite a still mixed backdrop.Narrativ-Update • Dec 03
ROG: Pipeline Readouts And Commercial Execution Will Shape Balanced Risk Reward Ahead
Analysts modestly raise their price target on Roche Holding, reflecting an updated fair value estimate of approximately CHF 312 from about CHF 305 as they factor in slightly stronger long term revenue growth, improving margins, and supportive readthroughs from recent pipeline and partnership developments. Analyst Commentary Recent Street commentary around Roche continues to frame the company as a strategically important player in oncology, ophthalmology, and digital enablement, while also highlighting competitive and execution risks that temper upside expectations.Narrativ-Update • Nov 19
ROG: Sector Pressures And Mixed Trial Results Will Shape Performance Ahead
Roche Holding’s analyst price target has been raised by CHF 10 to CHF 255. Analysts cite moderate adjustments to fair value estimates, along with continued caution regarding recent trial outcomes and sector dynamics.Analyseartikel • Aug 20
Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)
SWX:ROG 1 Year Share Price vs Fair Value Explore Roche Holding's Fair Values from the Community and select yours With a...Neues Narrativ • Feb 04
Roche Holding will see a 4.2576% revenue growth shaking the market
### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
Neues Narrativ • Feb 02
Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025
Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | CHF 13b |
| Sep 30 2025 | n/a | n/a | CHF 11b |
| Jun 30 2025 | n/a | n/a | CHF 9b |
| Mar 31 2025 | n/a | n/a | CHF 9b |
| Dec 31 2024 | n/a | n/a | CHF 8b |
| Sep 30 2024 | n/a | n/a | CHF 9b |
| Jun 30 2024 | n/a | n/a | CHF 11b |
| Mar 31 2024 | n/a | n/a | CHF 11b |
| Dec 31 2023 | n/a | n/a | CHF 11b |
| Sep 30 2023 | n/a | n/a | CHF 11b |
| Jun 30 2023 | n/a | n/a | CHF 11b |
| Mar 31 2023 | n/a | n/a | CHF 12b |
| Dec 31 2022 | CHF 5m | CHF 1m | CHF 12b |
| Sep 30 2022 | n/a | n/a | CHF 14b |
| Jun 30 2022 | n/a | n/a | CHF 15b |
| Mar 31 2022 | n/a | n/a | CHF 14b |
| Dec 31 2021 | CHF 4m | CHF 1m | CHF 14b |
| Sep 30 2021 | n/a | n/a | CHF 14b |
| Jun 30 2021 | n/a | n/a | CHF 14b |
| Mar 31 2021 | n/a | n/a | CHF 14b |
| Dec 31 2020 | CHF 4m | CHF 879k | CHF 14b |
| Sep 30 2020 | n/a | n/a | CHF 14b |
| Jun 30 2020 | n/a | n/a | CHF 13b |
| Mar 31 2020 | n/a | n/a | CHF 13b |
| Dec 31 2019 | CHF 2m | CHF 609k | CHF 13b |
Vergütung im Vergleich zum Markt: Unzureichende Daten, um festzustellen, ob die Gesamtvergütung von Thomas im Vergleich zu Unternehmen ähnlicher Größe auf dem Markt Swiss angemessen ist.
Entschädigung vs. Einkommen: ThomasDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.
Geschäftsführer
Thomas Schinecker (50 yo)
3yrs
Amtszeit
CHF 5,335,592
Vergütung
Dr. Thomas Schinecker is Chairman of the Board of Roche Holdings, Inc. from March 14, 2023. Dr. Schinecker is Director since March 27, 2025 at Chugai Pharmaceutical Co., Ltd. He serves as Chairman of the B...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Executive Chairman | 13yrs | CHF 11.48m | 0.045% CHF 115.3m | |
| Group Chief Executive Officer | 3yrs | CHF 5.34m | 0.00045% CHF 1.2m | |
| Chief Financial Officer | 14.9yrs | CHF 6.05m | 0.0066% CHF 17.1m | |
| Head of Investor Relations | no data | keine Daten | keine Daten | |
| General Counsel | 5.9yrs | keine Daten | keine Daten | |
| Chief Compliance Officer | 6.2yrs | keine Daten | keine Daten | |
| Head of Group Communications | less than a year | keine Daten | keine Daten | |
| Chief People Officer | 10yrs | CHF 4.25m | 0.0022% CHF 5.6m | |
| Head of Group Media Relations | no data | keine Daten | keine Daten | |
| Head of Corporate Business Development | no data | keine Daten | keine Daten | |
| Senior Vice President of Immunology | no data | keine Daten | keine Daten | |
| Global Head of Ophthalmology Roche pRED | no data | keine Daten | keine Daten |
6.0yrs
Durchschnittliche Betriebszugehörigkeit
55.5yo
Durchschnittliches Alter
Erfahrenes Management: Das Managementteam von ROG ist erfahren und erfahren (durchschnittliche Amtszeit von 6 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Executive Chairman | 13yrs | CHF 11.48m | 0.045% CHF 115.3m | |
| Director | 3yrs | keine Daten | 0.00063% CHF 1.6m | |
| Independent Vice Chairman | 30.2yrs | CHF 400.00k | 3.54% CHF 9.1b | |
| Independent Non Executive Director | 6yrs | CHF 360.00k | 0.00050% CHF 1.3m | |
| Non-Executive Independent Director | 11.2yrs | CHF 346.71k | 0% CHF 0 | |
| Non-Executive Independent Director | 9yrs | CHF 336.16k | 0.00059% CHF 1.5m | |
| Director | no data | keine Daten | keine Daten | |
| Non-Executive Independent Director | 6yrs | CHF 394.67k | keine Daten | |
| Director | 3yrs | keine Daten | keine Daten | |
| Independent Non-Executive Director | 4yrs | CHF 272.50k | keine Daten |
6.0yrs
Durchschnittliche Betriebszugehörigkeit
57.5yo
Durchschnittliches Alter
Erfahrener Vorstand: ROGDie Vorstandsmitglieder gelten als erfahren (6 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/03/16 07:25 |
| Aktienkurs zum Tagesende | 2026/03/16 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Roche Holding AG wird von 44 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| John Staszak | Argus Research Company |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Mark Purcell | Barclays |